638 reports of this reaction
4.6% of all LIDOCAINE HYDROCHLORIDE ANHYDROUS reports
#1 most reported adverse reaction
INFUSION SITE PAIN is the #1 most commonly reported adverse reaction for LIDOCAINE HYDROCHLORIDE ANHYDROUS, manufactured by Spectra Medical Devices, LLC. There are 638 FDA adverse event reports linking LIDOCAINE HYDROCHLORIDE ANHYDROUS to INFUSION SITE PAIN. This represents approximately 4.6% of all 13,967 adverse event reports for this drug.
Patients taking LIDOCAINE HYDROCHLORIDE ANHYDROUS who experience infusion site pain should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
INFUSION SITE PAIN is moderately reported among LIDOCAINE HYDROCHLORIDE ANHYDROUS users, representing a notable but not dominant share of adverse events.
In addition to infusion site pain, the following adverse reactions have been reported for LIDOCAINE HYDROCHLORIDE ANHYDROUS:
The following drugs have also been linked to infusion site pain in FDA adverse event reports:
INFUSION SITE PAIN has been reported as an adverse event in 638 FDA reports for LIDOCAINE HYDROCHLORIDE ANHYDROUS. This does not prove causation, but indicates an association observed in post-market surveillance data.
INFUSION SITE PAIN accounts for approximately 4.6% of all adverse event reports for LIDOCAINE HYDROCHLORIDE ANHYDROUS, making it one of the most commonly reported side effect.
If you experience infusion site pain while taking LIDOCAINE HYDROCHLORIDE ANHYDROUS, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.